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Bacterial LPS (endotoxin) has been implicated in the pathogenesis of acute liver disease through its induction of 
the proinflammatory cytokine TNF-α. TNF-α is a key determinant of the outcome in a well-established mouse 
model of acute liver failure during septic shock. One possible mechanism for regulating TNF-α expression 
is through the control of protein elongation during translation, which would allow rapid cell adaptation to 
physiological changes. However, the regulation of translational elongation is poorly understood. We found that 
expression of p38γ/δ MAPK proteins is required for the elongation of nascent TNF-α protein in macrophages. 
The MKK3/6-p38γ/δ pathway mediated an inhibitory phosphorylation of eukaryotic elongation factor 2 (eEF2) 
kinase, which in turn promoted eEF2 activation (dephosphorylation) and subsequent TNF-α elongation. These 
results identify a new signaling pathway that regulates TNF-α production in LPS-induced liver damage and sug-
gest potential cell-specific therapeutic targets for liver diseases in which TNF-α production is involved.
Introduction
Infection and tissue injury trigger a protective inflammatory 
response that mobilizes a variety of effector mechanisms to con-
tain and eliminate the injurious agent (1). Hepatic and circulating 
inflammatory cytokines initiate a positive feedback loop on the 
innate immune system (2); although cytokine production pro-
tects against pathogenic stimuli, it can cause more damage than 
the initiating event if its magnitude and duration are not strictly 
controlled by intrinsic negative regulators (1).
The cytokine TNF-α has been identified as a key regulator of the 
inflammatory response in animal models of fulminant hepatitis 
(3). Elevated concentrations of this proinflammatory cytokine are 
also found in acute and chronic inflammatory conditions, includ-
ing trauma, sepsis, and rheumatoid arthritis (4). Upon binding to 
its receptors, TNF-α initiates several intracellular signaling cas-
cades that influence cell survival, death, differentiation, prolifera-
tion, and migration (5, 6).
TNF-α signaling is particularly important in the liver. While it 
mediates hepatocyte survival and proliferation, it is also impli-
cated in liver failure, since it triggers hepatocyte apoptosis and 
leads to upregulation of key adhesion molecules and chemokines 
involved in leukocyte migration and infiltration (6, 7). A well-
established mouse model of acute liver failure and septic shock is 
the in vivo administration of bacterial LPS and D-galactosamine 
(D-gal), which strongly induce endogenous TNF-α and other 
cytokines that cause liver damage (8, 9).
TNF-α signaling can be mediated by protein kinases and phos-
phatases, in particular the MAPK family members ERK, JNK, 
and p38 MAPK. The p38 MAPK pathway transduces a variety 
of extracellular signals regulating cellular responses to stress, 
being implicated in cell proliferation, differentiation, and apop-
tosis (10, 11). Four p38 MAPK family members have been identi-
fied: p38α, p38β, p38γ, and p38δ, also known as stress-activated 
kinase 2 a (SAPK2a), SAPK2b, SAPK3, and SAPK4 (10, 12, 13). 
The p38 MAPK family can be further divided into 2 subsets, 
with p38α and p38β in one group and p38γ and p38δ in the 
other. All these kinases are activated by double phosphorylation 
mediated by the upstream kinases MKK3 and MKK6 (14, 15). 
To date, the best-characterized p38 isoform is p38α. This iso-
form is required for macrophage inflammatory responses (1), 
but in hepatocytes prevents endotoxin-induced liver damage 
(16, 17). Studies using inhibitors suggested that p38α and p38β 
cooperate in inflammatory processes; however, p38β-knockout 
mice show no differences in several in vivo and in vitro models 
of inflammation (18). Less is known about the role of the p38γ 
and p38δ MAPK. p38δ is known to phosphorylate eukaryotic 
elongation factor 2 (eEF2) kinase (eEF2K), inhibiting its activity 
(19). eEF2K blocks mRNA translation into protein through an 
inhibitory phosphorylation of eEF2.
The rate-limiting step in mRNA translation is thought to be the 
initiation step; however, far less is known about the regulation of 
the elongation step of protein biosynthesis (20). The process of 
peptide-chain elongation is at least partially regulated by eEF2 
phosphorylation/dephosphorylation events induced by diverse 
stimuli (21). Moreover, the phosphorylation state of the upstream 
kinase eEF2K can be modulated by signaling molecules that regu-
late the activity of this factor, such as mTOR and MAPKs, includ-
ing p38 kinases (19, 21–23). Because these kinases are activated 
by different stimuli, it is expected that the regulation of eEF2 will 
be important in cell adaptation to different physiological states. 
Here, we show that p38δ and p38γ expressed in myeloid cells 
promote eEF2 activity and, in consequence, TNF-α production 
and the inflammatory response. By blocking p38γ/δ activity in 
myeloid macrophages, we were able to suppress hepatitis caused 
by LPS-induced TNF-α expression.
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Results
MKK3 and MKK6 collaborate in LPS-induced hepatitis. To study the 
role of p38 MAPK signaling in hepatitis, we examined the effect of 
D-gal+LPS treatment on mice deficient for the upstream kinases 
MKK3 and MKK6. No differences in mortality where detected in 
Mkk3–/– or Mkk6–/– mice compared with WT animals (Supplemen-
tal Figure 1A; supplemental material available online with this 
article; doi:10.1172/JCI65124DS1). However, Mkk3–/– mice pres-
ent less severe liver hemorrhage (Supplemental Figure 1B) and 
Mkk6–/– liver apoptosis was significantly reduced (Supplemental 
Figure 1
ΔMKK3/6 mice are protected against LPS-induced liver damage. WT and Mkk3–/–Mkk6–/+ mice (ΔMKK3/6) were treated with D-gal+LPS or saline. (A) 
Survival curves after D-gal+LPS injection (n = 21). Survival curves were created with the Kaplan-Meier method and compared by log-rank (Mantel-
Cox) test. (B) Livers were removed at 6 hours after injection. Panels show representative H&E-stained liver sections and livers. The chart presents 
hemorrhagic area as a percentage of the total area (n = 6–8). Scale bar: 50 μm. (C) Serum transaminase activity at 4 and 6 hours after injection 
(n = 10). (D) Liver extracts were examined by immunoblot with antibodies to cleaved PARP, cleaved caspase 3, caspase 3, phospho-Jun and GAPDH 
(n = 6–8). (E) ELISA analysis of serum TNF-α and IL-6 at different times after injection (n = 16). Data are means ± SD. **P < 0.01; ***P < 0.001 (2-way 
ANOVA coupled to Bonferroni’s post tests).
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Figure 1C). Levels of alanine transaminase (ALT) and aspartate 
aminotrasferase (AST), 2 well-established markers of hepatic 
necrosis, were not altered in Mkk3–/– mice, but were significantly 
reduced in Mkk6–/– mice, thus showing an effect on liver necrosis 
(Supplemental Figure 1D).
The p38 MAPK pathway is a key regulator of the expression 
of inflammatory cytokines, including IL-6 and TNF-α, the main 
determinant of LPS-stimulated liver damage (24–27). Circulating 
levels of TNF-α and IL-6 after D-gal+LPS injection did not differ 
between WT mice and the Mkk3–/– or Mkk6–/– mice (Supplemen-
tal Figure 2A). In vitro stimulation of isolated BM macrophages 
from these mice with LPS also revealed no differences in pro-
liferation rate or released TNF-α and IL-6 levels (Supplemental 
Figure 2, B and C). Moreover, supernatants from WT, Mkk3–/–, 
and Mkk6–/– macrophages induce apoptosis similarly in cultured 
hepatocytes (not shown), thus indicating that the partial protec-
tion against LPS-induced liver apoptosis was not due to circulat-
ing macrophages.
Neutrophil infiltration can cause mild to severe liver dam-
age (28), and p38α was recently shown to control neutrophil 
cytokine production (29). We examined liver myeloid leukocytes 
based on CD11b, Gr-1, F4/80, and Ly6C markers (Supplemental 
Figure 2D and ref. 30). Analysis of liver cell populations revealed 
that D-gal+LPS injection increased liver infiltration by neutro-
phils (CD11b+Gr-1hi) in WT mice, but this effect was impaired in 
Mkk3–/– and Mkk6–/– mice (Supplemental Figure 1E). To investigate 
the potential involvement of liver neutrophils and macrophages in 
the protection detected in Mkk3–/– and Mkk6–/– mice, we isolated 
leukocytes from the livers of WT, Mkk3–/–, and Mkk6–/– mice and 
stimulated them with LPS. Whereas the percentage of neutrophils 
expressing TNF-α was the same in all genotypes, the percentage of 
monocytes (CD11b+Gr-1intermediate) expressing TNF-α was higher in 
WT mice than in Mkk3–/– and Mkk6–/– mice (Supplemental Figure 
1F), indicating that the protection against LPS-induced liver apop-
tosis could be mediated by liver inflammatory monocytes.
Mkk3–/–Mkk6–/+ mice are protected against LPS-induced liver failure. 
MKK3 and MKK6 show functional redundancy in the activation 
of p38 MAPK (14), and while single mutants are viable, doubly 
deficient Mkk3–/–Mkk6–/– and Mkk3–/+Mkk6–/– mice die early in 
embryogenesis. To minimize interference from redundant actions, 
we used Mkk3–/– Mkk6–/+ (ΔMKK3/6) mice, which are viable (14). 
As expected, ΔMKK3/6 mice were protected against LPS-induced 
hepatotoxicity, showing milder hemorrhage and better survival 
than WT mice (Figure 1, A and B). Immunoblot analysis demon-
strated that D-gal+LPS injection activated caspase 3 and PARP 
cleavage in WT liver but not in ΔMKK3/6 livers (Figure 1D). 
Moreover, circulating transaminases were reduced in ΔMKK3/6 
mice, indicating a reduction in liver necrosis (Figure 1C). These 
data demonstrate that MKK3/6 deficiency severely limits LPS-
stimulated hepatic apoptosis. Examination of serum TNF-α after 
D-gal+LPS injection revealed that the marked increase in TNF-α 
concentration observed in WT and singly deficient mice was not 
detected in ΔMKK3/6 mice (Figure 1E). Serum IL-6 was also lower 
in ΔMKK3/6 mice (Figure 1E). The loss of LPS-stimulated TNF-α 
expression in ΔMKK3/6 mice might account for the finding that 
LPS activation of JNK pathway in the livers of WT mice was not 
seen in ΔMKK3/6 mice (Figure 1D).
MKK3 and MKK6 are required for neutrophil migration after LPS injec-
tion. The lower TNF-α production in ΔMKK3/6 mice could be a 
consequence of the lower leukocyte infiltration in liver. To address 
this, we analyzed myeloid cell migration after D-gal+LPS injection. 
Quantification of liver chemokines showed that in WT mice, LPS 
treatment increased mRNA expression of molecules important for 
migration of macrophages (MCP1 and ICAM) and neutrophils 
(KC, MIP2), whereas induction of these chemokines and adhesion 
molecules was decreased in the livers of ΔMKK3/6 mice (Figure 
2A). Phenotypic characterization of liver-infiltrating leukocytes 
from control and D-gal+LPS–treated livers revealed a significant 
increase in neutrophils in the inflammatory cell infiltrate of WT 
mice that was impaired in ΔMKK3/6 mice (Figure 2B), consistent 
with the reduced disease severity (28). However, the percentages 
of macrophages and monocytes did not differ between genotypes 
(Figure 2B). These findings correlated with lower RNA expression 
of neutrophil markers (Elastase 2, Ly6G) in the livers of LPS-inject-
ed ΔMKK3/6 mice (Supplemental Figure 3A).
The reduced liver neutrophil infiltration in ΔMKK3/6 mice 
could be due either to impaired neutrophil release from BM or 
to a defect in cell migration. The levels of circulating neutrophils 
after LPS injection showed a sharp increase in WT mice that was 
absent in ΔMKK3/6 mice (Figure 2C). These data show that the 
reduced neutrophil infiltration in liver is in part caused by low-
ered neutrophil mobilization from the BM. To investigate whether 
the low circulating levels of TNF-α in ΔMKK3/6 mice might be 
responsible for this alteration, we injected TNF-α+D-gal into WT 
and ΔMKK3/6 mice, resulting in increased circulating neutrophil 
levels in both genotypes (Supplemental Figure 3B). These data 
indicate that the defect in migration is secondary to the low pro-
duction of TNF-α in ΔMKK3/6 mice.
MKK3 and MKK6 regulate TNF-α production by macrophages. To 
investigate the molecular mechanism underlying reduced circu-
lating TNF-α in ΔMKK3/6 mice, we treated BM-derived macro-
phages from WT and ΔMKK3/6 mice with LPS. Whereas treat-
ment of WT macrophages with LPS activated JNK, ERK, and p38 
MAPK, in ΔMKK3/6 macrophages the activation of p38 MAPK 
was impaired (Supplemental Figure 3C). The ΔMKK3/6 macro-
phages also secreted markedly reduced amounts of TNF-α and 
IL-6 compared with WT macrophages, confirming that MKK3/6 
deficiency causes major defects in TNF-α production (Supple-
mental Figure 3D). Further analysis showed that neutrophils and 
Kupffer cells, 2 other myeloid cell types implicated in liver dam-
age, also secreted reduced amounts of TNF-α and IL-6 (Supple-
mental Figure 3, E and F). However, in vivo analysis indicated that 
although the percentage of liver neutrophils expressing TNF-α 
after D-gal+LPS injection was the same in both genotypes, the 
percentage of monocytes and macrophages expressing TNF-α was 
higher in WT livers (Figure 2D).
To confirm that reduced cytokine production by liver mac-
rophages is responsible for the protection against hepatocyte 
apoptosis in ΔMKK3/6 mice, we stimulated primary hepatocytes 
with conditioned medium from LPS-treated BM-derived macro-
phages. Conditioned medium from LPS-treated WT macrophages 
increased hepatocyte apoptosis, measured by cleavage of caspase 
3 and PARP, whereas conditioned medium from LPS-treated 
ΔMKK3/6 macrophages had no effect (Supplemental Figure 3G).
MKK3 and MKK6 are not required for TNF-α–induced liver damage. 
Our results so far show that MKK3/6 deficiency causes decreased 
TNF-α production in a TNF-α–dependent hepatitis model. This 
implies that ΔMKK3/6 mice are defective for TNF-α secretion, but 
not TNF-α responsiveness. To test this, we treated mice with TNF-α, 
finding that TNF-α caused similar mortality and liver damage in 
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Figure 2
ΔMKK3/6 mice have lower liver inflammation 
after LPS injection. WT and ΔMKK3/6 mice were 
treated with D-gal+LPS or saline. (A) Total RNA 
was extracted from livers 6 hours after treat-
ment and chemokine mRNA levels determined 
by qRT-PCR. mRNA expression was normal-
ized to Gapdh (n = 5–8). (B) Liver myeloid 
subsets (CD11b+Gr-1hi, CD11b+Gr-1intermediate, 
CD11b+Gr-1–) were assessed by flow cytom-
etry of liver leukocytes isolated from WT and 
ΔMKK3/6 mice 4 and 6 hours after treatment. 
Representative dot plots are shown. Bar charts 
show each myeloid population as the percent-
age of total intrahepatic leukocyte population 
(n = 7). (C) Neutrophils as a percentage of circu-
lating leukocytes, measured in total blood 4 hours 
after injection (n = 5–8). (D) TNF-α and IL-12 pro-
duction by liver myeloid subsets were analyzed 
by intracellular staining in neutrophils (CD11b+ 
Gr-1hi), monocytes (CD11b+Gr-1intermediate) and 
CD11b+Gr-1– myeloid cells isolated from WT and 
ΔMKK3/6 mice 4 and 6 hours after injection. Rep-
resentative dot plots are shown for all treatment 
groups, and bar charts show TNF-α–positive 
cells as the percentage of each myeloid popu-
lation (n = 7). Data are means ± SD. *P < 0.05; 
**P < 0.01; ***P < 0.001 (2-way ANOVA coupled 
to Bonferroni’s post tests).
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WT and ΔMKK3/6 mice (Figure 3, A and B). Immunoblot analy-
sis demonstrated that TNF-α stimulated a similar degree of cas-
pase 3 and PARP cleavage (Figure 3C). Moreover, TNF-α induced 
the same levels of neutrophil liver infiltration in both genotypes 
(Figure 3D). To confirm that the protection was due to defec-
tive cytokine production and not to a protective loss of respon-
siveness to TNF-α, we treated primary hepatocytes from WT or 
ΔMKK3/6 mice with TNF-α and the protein synthesis inhibitor 
cycloheximide (CHX). Both hepatocyte populations presented the 
same level of apoptosis (Figure 3E). These data demonstrate that 
ΔMKK3/6 mice do not exhibit resistance to TNF-α–induced hepa-
titis and indicate that the primary protection against LPS-induced 
hepatitis in these mice is due to an inability to produce TNF-α.
MKK3 and MKK6 are required in the hematopoietic compartment for 
LPS-induced liver damage. The source of TNF-α in mouse models 
of hepatitis is the hematopoietic compartment (31, 32). There-
Figure 3
ΔMKK3/6 mice are not protected against TNF-α–induced liver damage. WT and ΔMKK3/6 mice were i.v. injected with 10 μg/kg ΤΝF-α plus 1 g/kg D-gal 
(TNF-α/Gal) or with saline. (A) Survival curves after TNF-α/Gal injection (n = 13). Survival curves were created with the Kaplan-Meier method and 
compared by log-rank (Mantel-Cox) test. (B) Representative H&E-stained sections of livers extracted 6 hours after injection. The chart presents hem-
orrhagic area as a percentage of the total area (n = 8). Scale bar: 50 μm. (C) Liver extracts were examined by immunoblot analysis for cleaved PARP, 
cleaved caspase 3, caspase 3, phospho-Jun, and GAPDH (n = 6–8). (D) Liver myeloid subsets (CD11b+Gr-1hi, CD11b+Gr-1intermediate, CD11b+Gr-1–) 
were assessed by flow cytometry of liver leukocytes isolated from WT and ΔMKK3/6 mice 4 and 6 hours after treatment. Representative dot plots 
are shown. Bar charts show each myeloid subset as a percentage of the total intrahepatic leukocyte population (n = 4–6). (E) Immunoblot of cleaved 
caspase 3, caspase 3, and GAPDH in WT and ΔMKK3/6 primary hepatocytes treated with TNF-α (20 ng/ml) plus CHX (100 μg/ml). Data are means 
± SD. No significant differences were found (2-way ANOVA coupled to Bonferroni’s post tests).
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Figure 4
ΔMKK3/6 hematopoietic cells protect mice against hepatitis. Lethally irradiated WT mice were reconstituted with BM from WT or ΔMKK3/6 
mice. Mice were treated with D-gal+LPS 2 months after transplantation. (A) 2 × 107 freshly prepared CD45.2 whole BM mononuclear cells were 
transplanted into lethally irradiated B6.SJL (CD45.1) mice, and engraftment by CD45.2 cells (%) was analyzed by antibody staining and FACS 
of peripheral blood after 4 months. Left panels: representative FACS dot plot of CD45.1 and CD45.2 expression in cells isolated from the blood 
of transplanted mice. Right panels: representative FACS dot plot of CD45.1 and CD45.2 expression in F4/80-positive cells isolated from the 
liver of transplanted mice (n = 3). (B) Survival curves after D-gal+LPS injection (n = 10). Survival curves were created with the Kaplan-Meier 
method and compared by log-rank (Mantel-Cox) test. (C) Representative H&E-stained sections of livers extracted 6 hours after injection. The 
chart presents hemorrhagic area as a percentage of the total area (n = 5–8). Scale bar: 50 μm. (D) Serum transaminase activity at 4 and 6 
hours after injection (n = 5–8). (E) ELISA of serum TNF-α and IL-6 at different times after injection (n = 5–8). Data are means ± SD. *P < 0.05; 
**P < 0.01; ***P < 0.001 (2-way ANOVA coupled to Bonferroni’s post tests).
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fore, if defective TNF-α expression accounts for the protection of 
ΔMKK3/6 mice against TNF-α–dependent hepatitis, transplan-
tation of the hematopoietic compartment of ΔMKK3/6 mice to 
immunodeficient donors should confer this protection. To test 
the role of hematopoietic cells, we constructed radiation chime-
ras by transplanting BM from WT and ΔMKK3/6 donor mice 
into lethally irradiated congenic WT and ΔMKK3/6 recipients. 
Efficient reconstitution of B6.SJL (CD45.1) mice with BM from 
WT C57BL/6J (CD45.2) or ΔMKK3/6 (CD45.2) mice was con-
firmed by flow cytometry analysis of peripheral blood leukocytes 
stained with antibodies to CD45.1/CD45.2. Moreover, analysis of 
Kupffer cells (F4/80+) in the liver of recipients after transplanta-
tion showed that more than 90% of Kupffer cells originated from 
the donor mice (Figure 4A).
We found that lethally irradiated mice reconstituted with 
ΔMKK3/6 BM were indeed protected against LPS-induced mor-
tality and exhibited lower levels of LPS-stimulated serum TNF-α 
and hepatic damage than mice reconstituted with WT BM (Figure 
4, B–E). These data confirm that MKK3 and MKK6 expressed in 
hematopoietic cells play a critical role in the expression of TNF-α 
that leads to the development of hepatitis.
Inhibition of p38γ and p38δ protects against LPS-induced hepatitis. 
MKK3 and MKK6 are the main regulators of the α, β, γ, and δ 
p38 MAPK isoforms. To determine which isoforms mediate 
MKK3/MKK6-induced TNF-α expression, we analyzed the effect 
on D-gal+LPS–induced liver damage of 2 inhibitors: SB203580, 
which inhibits p38α and p38β, and BIRB796, which inhibits 
all isoforms (33). We treated mice with BIRB796, SB203580, or 
DMSO prior to LPS injection. We first examined the specific 
action of these inhibitors on MAPK pathway activity. Both com-
pounds efficiently inhibited p38α/β, as shown by the loss of the 
phosphorylation of the known p38α substrate HSP27 (Supple-
mental Figure 4A and ref. 34). In contrast, only BIRB796 was 
able to inhibit p38δ activation, as indicated by suppression of the 
phosphorylation of its substrate, eEF2K (19). No changes in ERK 
or JNK phosphorylation were observed (Supplemental Figure 4A). 
Injection of BIRB796 into WT mice protected against D-gal+LPS–
induced liver damage, whereas SB203580 exacerbated liver dam-
age (hemorrhage, apoptosis, and necrosis) (Supplemental Figure 
4, B–D). Injection of BIRB796 also reduced serum levels of IL-6 
and TNF-α in D-gal+LPS–treated mice (Supplemental Figure 
4E). These results suggest that LPS-induced liver injury might be 
mediated by p38γ and p38δ.
Myeloid expression of p38γ and p38δ is required for LPS-induced hep-
atitis. To investigate the role of p38γ and p38δ in LPS-induced 
hepatitis, we generated mice with myeloid cell–specific ablation of 
these p38 isoforms, separately and in combination. Mice carrying 
conditional loxP-flanked alleles for p38γ, p38δ, and p38γ/δ (p38γfl, 
p38δfl, and p38γ/δfl mice) were crossed with Lyzs-cre transgenic 
mice (35), yielding p38γLyz-KO, p38δLyz-KO, and p38γ/δLyz-KO mice. 
Immunoblot analysis confirmed efficient ablation of the appro-
priate kinases in macrophages, neutrophils, and Kupffer cells 
(Supplemental Figure 5, A and B).
Compared with control Lyzs-cre transgenic mice, p38δLyz-KO 
and p38γ/δLyz-KO mice showed a delay in mortality in response 
to injection of D-gal+LPS (Figure 5A). These mice were also 
protected against liver damage and apoptosis, showing mild-
er liver hemorrhaging, reduced serum levels of ALT and AST, 
and reduced caspase 3 cleavage (Figure 5, B–E). Analysis of 
cytokines revealed significantly lower circulating TNF-α and 
IL-6 in LPS-injected p38δLyz-KO and p38γ/δLyz-KO mice than in 
similarly treated Lyzs-cre controls (Figure 5F). Other chemo-
kines involved in leukocyte migration (MIP1α and MIP1β) were 
also reduced (Supplemental Figure 6). In contrast, p38γLyz-KO 
mice presented only a modest effect on circulating TNF-α levels 
and no differences in the levels of other cytokines (Figure 5F 
and Supplemental Figure 6).
The phenotype found in p38γ/δLyz-KO mice might reflect the 
function of these kinases in several myeloid cell populations impli-
cated in D-gal+LPS damage (such as neutrophils, Kupffer cells, 
and macrophages). Analysis of these cell types in Lyzs-cre mice 
revealed expression of p38γ and p38δ in macrophages, predomi-
nant expression of p38δ in neutrophils, and exclusive expression 
of p38γ in Kupffer cells (Supplemental Figure 5A). Moreover, p38γ 
is strongly activated in Kupffer cells by LPS or TNF-α treatment 
(Supplemental Figure 5B), as judged by the impaired p38 phos-
phorylation observed by FACS in Kupffer cells from p38γ/δLyz-KO 
mice. Furthermore, analysis of phospho-p38 by Western blot con-
firmed that p38γ was the isoform activated in these cells after LPS 
treatment (Supplemental Figure 5C). LPS and TNF-α also activat-
ed p38γ and p38δ in macrophages (Figure 6), while in neutrophils, 
p38α was the only isoform activated after either stimulus (Supple-
mental Figure 5, B and D). Since neutrophils, Kupffer cells, and 
macrophages express p38γ, p38δ, or both isoforms, any of these 
cell populations could have a role in the protection observed in 
p38γ/δLyz-KO mice. We therefore analyzed the different leukocyte 
populations that infiltrated the liver after D-gal+LPS injection. 
Analysis of liver-infiltrating leukocytes showed lower numbers 
of neutrophils in LPS-injected p38γ/δLyz-KO mice than in similarly 
treated Lyzs-cre mice. However, this reduction was not significant 
in LPS-injected p38δLyz-KO mice (Figure 5G). None of the myeloid-
specific p38-deficient mice showed alterations in the percentages 
of infiltrated macrophages or monocytes. Collectively, these data 
show that p38γ/δLyz-KO mice are more strongly affected than either 
of the single conditional knockouts; however, p38δLyz-KO animals 
have a stronger phenotype than p38γLyz-KO mice, indicating partial 
Figure 5
p38γ/δLyz-KO mice are protected against LPS-induced liver damage. 
p38γLyz-KO, p38δLyz-KO, p38γ/δLyz-KO, and control Lyzs-cre transgenic 
mice were injected with D-gal+LPS or saline. (A) Mouse survival after 
D-gal+LPS injection (n = 14). Survival curves were created with the 
Kaplan-Meier method and compared by log-rank (Mantel-Cox) test. (B) 
Livers were removed at 6 hours after injection. Panels show representa-
tive H&E-stained liver sections and livers (n = 5–8). Scale bar: 50 μm. (C) 
Hemorrhagic area as a percentage of the total area on H&E-stained liver 
sections (n = 5–8). (D) Immunoblot analysis of liver extracts (n = 5–8). 
(E) Serum transaminase activity at 6 hours after injection (n = 8–10). (F) 
ELISA of serum TNF-α and IL-6 at different times after injection (n = 10). 
#P < 0.01 for Lyzs-cre versus p38δLyz-KO mice in TNF-α; *P < 0.001 for 
Lyzs-cre versus p38γ/δLyz-KO mice for TNF-α and for Lyzs-cre versus 
p38γ/δLyz-KO or p38δLyz-KO mice in IL-6 (n = 6–8). (G) Liver myeloid sub-
sets (CD11b+Gr-1hi, CD11b+Gr-1intermediate, CD11b+Gr-1–) were assessed 
by flow cytometry of liver leukocytes isolated from p38γLyz-KO, p38δLyz-KO, 
p38γ/δLyz-KO, and control Lyzs-cre transgenic mice 6 hours after injec-
tion. Representative dot plots are shown. Bar charts show each myeloid 
population as a percentage of the total intrahepatic leukocyte population 
(mean ± SD; n = 4–6). Circulating neutrophils in total blood were mea-
sured as a percentage of circulating leukocytes 4 hours after injection 
(n = 5–8). Data are means ± SD. **P < 0.01; ***P < 0.001 (2-way ANOVA 
coupled to Bonferroni’s post tests).
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gests an involvement of cytokine and chemokine production by acti-
vated Kupffer cells and infiltrated macrophages in the pathogenesis 
of liver damage (39). We therefore examined cytokine production by 
macrophages and Kupffer cells upon LPS treatment. ELISA analysis 
demonstrated that LPS-induced production of TNF-α and IL-6 was 
lower in p38γ/δLyz-KO macrophages and Kupffer cells than in Lyzs-
cre control cells (Figure 6A and Supplemental Figure 7C). Moreover, 
only the supernatant from macrophages of p38γ/δLyz-KO animals was 
unable to induce apoptosis in primary hepatocytes (Supplemen-
tal Figure 7A), and analysis of this supernatant indicated a defect 
in cytokine production (Figure 6A and Supplemental Figure 7B). 
Similarly, induction of apoptosis by supernatant from control Lyzs-
cre macrophages was blocked by addition of anti–TNF-α antibody, 
resulting in a protection similar to that obtained with p38γ/δLyz-KO 
supernatant (Supplemental Figure 7C). This finding thus indicates 
that the low TNF-α levels in p38γ/δLyz-KO macrophages and Kupffer 
cells could account for the protection against D-gal+LPS–induced 
liver damage.
p38γ and p38δ mediate TNF-α translation in myeloid cells by phos-
phorylating eEF2K. p38 MAPK can promote cytokine expression 
at the level of transcription, after transcription (by promoting 
mRNA stability), and translation (27, 40). Il6 mRNA expression 
was reduced in p38γ/δLyz-KO macrophages, but levels of Tnfa mRNA 
were comparable to those in Lyzs-cre macrophages (Figure 6B). 
The stability of Tnfa mRNA also showed no difference between the 
2 genotypes (Supplemental Figure 7F). The translational action of 
p38δ has been linked to eEF2 kinase, the enzyme that inactivates 
eEF2. This kinase is inhibited by p38δ-mediated phosphoryla-
tion on Ser359 and also by ribosomal protein S6 kinase–mediated 
phosphorylation on Ser366 (19, 23). Since little is known about 
the regulation of eEF2K in macrophages, we investigated the effect 
of p38γ/δ deletion on the phosphorylation of eEF2K and its down-
stream substrate eEF2. LPS stimulation of Lyzs-cre macrophages 
induced eEF2K phosphorylation on Ser359, but this was markedly 
impaired in p38γ/δLyz-KO macrophages (Figure 6C). This observa-
tion was also corroborated in Kupffer cells (Supplemental Figure 
7D). eEF2K phosphorylation in Lyzs-cre macrophages correlated 
with dephosphorylation of eEF2, implying activation of elonga-
tion. In contrast, p38γ/δLyz-KO macrophages sustained high levels of 
eEF2 phosphorylation after the stimulus, suggesting that elonga-
tion is abolished.
To assess whether eEF2 controls TNF-α elongation, we exam-
ined the binding of eEF2 to Tnfa mRNA in immunoprecipitates 
of mRNA-eEF2 complexes in RAW cells. RAW extracts were incu-
bated with anti-eEF2 or an isotype control antibody, and the 
presence of Tnfa mRNA in the immunoprecipitates was exam-
ined by quantitative (q) real-time PCR. High relative levels of 
Tnfa mRNA were detected in the anti-eEF2 immunoprecipitate, 
and this association was increased by LPS treatment (Figure 
6, E and F). High mRNA levels for Hif1a, a known eEF2 target, 
were also detected in the anti-eEF2 immunoprecipitate (Fig-
ure 6F). In contrast, Il6 mRNA levels did not differ between the 
anti-eEF2 and isotype control immunoprecipitates (Figure 6F). 
Pretreatment of RAW cells with BIRB796 abolished the asso-
ciation of eEF2 with Tnfa mRNA (Figure 6G). Moreover, Tnfa 
mRNA was detected in anti-eEF2 immunoprecipitates from 
LPS-treated Lyzs-cre or WT BM–derived macrophages but not 
in immunoprecipitates from similarly treated p38γ/δLyz-KO or 
ΔMKK3/6 macrophages (Figure 6, H and I). Together, our data 
indicate that Tnfa mRNA is a selective target of eEF2 and that 
redundancy between p38γ and p38δ, with a predominant role of 
p38δ. This overlapping action has been shown before and might 
account for the limited protection observed in single conditional 
knockouts (36, 37). We therefore used p38γ/δLyz-KO mice for further 
experiments. Further studies showed that the reduced neutrophil 
infiltration in liver is, in part, caused by lowered neutrophil mobi-
lization from the BM (Figure 5G), probably due to the defective 
production of TNF-α. Furthermore, measurement of TNF-α–
stimulated chemotaxis in a chamber assay revealed a slightly lower-
than-control mobility in p38γ/δLyz-KO neutrophils (Supplemental 
Figure 8A), and this effect was not increased by stimulation with a 
cytokine cocktail (Supplemental Figure 8B). Neutrophils produce 
several cytokines, and this function can be controlled by p38α (29). 
Examination of cytokine production in our system showed that 
p38γ/δLyz-KO neutrophils express slightly reduced levels of TNF-α 
and IL-6 after LPS treatment, but not sufficient to explain the phe-
notype observed (Supplemental Figure 8C).
To investigate whether the lower neutrophil infiltration in 
the livers of p38γ/δLyz-KO mice could account for the protection 
observed, we investigated whether neutrophil-specific depletion 
in Lyzs-cre mice results in milder liver damage upon D-gal+LPS 
treatment, similar to the phenotype of p38γ/δLyz-KO mice. GR1 is 
highly expressed on neutrophils, and anti-GR1 antibody treat-
ment has been shown to specifically deplete neutrophils (38). 
Treatment of mice with anti-GR1 one day before D-gal+LPS 
injection completely depleted Gr1+ neutrophils (Supplemental 
Figure 8D). Neutrophil depletion did not affect liver damage in 
Lyzs-cre mice, and neither did it abolish the protection observed in 
p38γ/δLyz-KO, as assessed by the levels of ALT and AST, cleaved cas-
pase 3, and PARP, or liver damage observed in H&E-stained sec-
tions (Supplemental Figure 8, E–G).
These data indicate that neutrophils do not play a dominant role 
in the protection against D-gal+LPS–stimulated hepatic damage 
observed in p38γ/δLyz-KO mice and therefore indicate that a different 
myeloid cell type underlies this phenotype. Available evidence sug-
Figure 6
p38γ/δLyz-KO macrophages promote TNF-α translation through phosphory-
lation of eEF2 kinase. (A–D) BM-derived macrophages from p38γ/δLyz-KO 
and Lyzs-cre mice were treated with LPS (10 μg/ml) or TNF-α (20 ng/ml). 
Data were analyzed by 2-way ANOVA coupled to Bonferroni’s post tests. 
(A) ELISA of TNF-α and IL-6 in supernatants. (B) qRT-PCR of Tnfa and 
Il6 mRNA normalized to Gapdh. (C) Immunoblot of BM-derived macro-
phage (BMM) lysates. (D) Flow cytometry of phospho-p38 in BM-derived 
macrophages stimulated with LPS and TNF-α for 30 minutes. Intracellular 
phospho-p38 is depicted in black; gray corresponds to the isotype control. 
(E–I) Cells were treated with LPS. Tnfa mRNA was detected by qRT-PCR 
in immunoprecipitates (1 mg protein) obtained with anti-eEF2. mRNA 
amounts are expressed relative to the amount detected in control IgG 
immunoprecipitates. Data were analyzed by Student’s t test unless oth-
erwise indicated. (E) Tnfa mRNA in RAW 264.7 cell immunoprecipitates. 
(F) Tnfa, Hif1a, and Il6 mRNA in RAW 264.7 cell immunoprecipitates. 
The presence of eEF2 was determined by immunoblot (upper panel) 
and quantified with ImageJ (1-way ANOVA coupled to Bonferroni’s post 
tests). (G) RAW 264.7 cells were pretreated with DMSO or BIRB796 
(10 μM) for 30 minutes before stimulation with LPS (60 minutes). Tnfa 
mRNA was measured in immunoprecipitates. (H and I) Tnfa mRNA in 
immunoprecipitates of BM-derived macrophages from Lyzs-cre and 
38γ/δLyz-KO mice (H) or WT or ΔMKK3/6 mice (I) after stimulation (60 min-
utes). eEF2 in immunoprecipitates was detected by immunoblot (upper 
panel). Data are means ± SD (n = 4). *P < 0.05; **P < 0.01; ***P < 0.001.
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trol cytokine production in myeloid cells. Our findings raise 3 key 
areas of interest: the specific role of myeloid cells, the involvement 
of p38γ/δ compared with that of the other kinases of the same 
family, and how acute inflammatory responses can be controlled 
through tight regulation of translational elongation.
Myeloid cells such as Kupffer cells and other macrophages are 
well known to be a critical source of TNF-α in LPS-induced hep-
atitis (14, 32). This specific role of hematopoietic cells is consis-
tent with our finding that the protective effects of MKK3/6 defi-
ciency are also present in irradiated WT mice reconstituted with 
ΔMKK3/6 BM (Figure 5). Furthermore, this protection was also 
observed in mice specifically lacking p38γ/δ in the myeloid com-
partment (Figure 6). Two cell types of special relevance in acute 
hepatitis are neutrophils and monocytes/macrophages (includ-
ing Kupffer cells), and both of these BM-derived cell populations 
are essential for the innate immune response (42). Monocytes/
macrophages bind to microbial constituents (such as LPS and 
cell wall constituents of Gram-positive bacteria), producing 
large amounts of pro- and antiinflammatory cytokines (3). Neu-
trophil recruitment and activation occur through TNF-α–medi-
ated chemokine production (3). This is evidenced by our find-
ing that low expression of TNF-α in ΔMKK3/6 or p38γ/δLyz-KO 
mice results in decreased chemokine production and neutrophil 
migration, an effect reversed by injection with TNF-α. We did 
not find, however, any evidence for a role of p38γ/δ in neutro-
phil migration, and we found only a minor effect on cytokine 
expression. This contrasts with the recent finding that p38α can 
control cytokine production by neutrophils (29), illustrating the 
different roles and clinical potential of p38 kinase isoforms as 
targets for preventing LPS-induced damage.
Previous reports have identified p38α as a key kinase involved in 
TNF-α production (43). p38α MAPK deficiency in macrophages 
results in decreased TNF-α production, with a modest effect on 
IL-6 expression (44). However, specific inhibition of this kinase 
has been shown to be hepatotoxic, hindering its clinical use. For 
example, the p38α inhibitor AMG 548 showed more than 85% 
inhibition of ex vivo LPS-induced TNF-α in healthy males, but 
its production and clinical use were suspended due to random 
liver enzyme elevations that were not dose or exposure dependent 
(45). Our results show that specific inhibition of p38α/β with 
SB203580 intensifies D-gal+LPS–induced liver damage, whereas 
BIRB796, which inhibits all 4 p38 isoforms (α/β/γ/δ) improves 
liver condition, including a reduction in apoptosis and necrosis. 
The toxicity associated with SB203580 might be caused by inhibi-
tion of p38α in hepatocytes, since mice with specific p38α defi-
ciency in hepatocytes have increased JNK activity and increased 
susceptibility to liver damage (17, 43). In clinical use, BIRB796 also 
produces some liver enzyme elevations (46), most likely because 
of inhibition of p38. Our findings indicate that the generation of 
inhibitors that specifically target p38γ/δ kinases might avoid the 
adverse effects found with p38α inhibitors.
Our results further show that p38γ/δ control macrophage pro-
duction of TNF-α by promoting protein elongation during trans-
lation by eEF2. Protein synthesis is tightly regulated at transcrip-
tional and posttranscriptional levels. Owing to the relatively long 
life time of mRNA transcripts, transcriptional regulation is com-
monly involved in slow, long-term cell responses, whereas immedi-
ate cell responses require posttranscriptional regulation of mRNA 
stability or translation. Two physiological situations requiring 
rapid regulation of protein synthesis are starvation and inflam-
the MKK3/6-p38γ/δ pathway, by releasing eEF2K-mediated inhi-
bition of eEF2 activity, promotes the translational elongation of 
TNF-α in macrophages.
eEF2 controls TNF-α translation elongation. To confirm eEF2 control 
of TNF-α translation elongation, we used a recombinant lentivi-
rus expressing an eEF2 shRNA (shEF2), which causes robust eEF2 
knockdown in RAW cells (Supplemental Figure 9A). In macro-
phages, shEF2-mediated loss of eEF2 caused a decrease in TNF-α 
production of a magnitude similar to that caused by loss of p38γ/δ 
(Figure 7A). In contrast, p38γ/δ-dependent IL-6 production was 
eEF2 independent (Figure 7A). These data indicate that the expres-
sion of TNF-α is controlled by eEF2, while the reduced IL-6 pro-
duction in p38γ/δLyz-KO mice is caused by a different mechanism, 
most likely the loss of p38γ/δ-regulated Il6 gene transcription.
To test the role of eEF2 in vivo, we injected mice with the shEF2 
lentivirus or control shRNA lentivirus 1 week before exposure to 
D-gal+LPS. Blood levels of TNF-α were strongly reduced by the 
shEF2-injected mice compared with controls (Figure 7B). More-
over, this reduction in TNF-α was associated with protection 
against hepatic cell death, measured by cleavage of caspase 3 and 
PARP and protection against hepatic necrosis, and measured by 
liver hemorrhage and blood levels of ALT and AST (Figure 7, C–E). 
Collectively, these data indicate that p38γ/δ MAPK proteins are 
required for the translation elongation of ΤΝF-α in macrophages 
mediated by phosphorylation of eEF2K and the activation of eEF2.
Discussion
In this study,we show that protein kinases p38γ/δ mediate the 
development of LPS-induced acute hepatitis by acting within a 
protein kinase signaling network that regulates the production of 
TNF-α by hematopoietic cells. MKK3 and MKK6 activate p38γ/δ 
(14, 15), which in turn phosphorylate and inactivate eEF2 kinase 
(41). Once eEF2K is inactivated, eEF2 is dephosphorylated and 
activated, allowing the translational elongation of nascent TNF-α. 
To our knowledge, this is the first report that eEF2 or p38γ/δ con-
Figure 7
eEF2 controls TNF-α elongation, and its gene silencing protects 
against LPS-induced liver damage. (A) BM-derived macrophages from 
Lyzs-cre and p38γ/δLyz-KO mice were transduced with GFP+ lentivirus 
expressing eEf2 shRNA (shEF2) or with empty vector (shΦ). ELISA of 
TNF-α and IL-6 in culture supernatants was performed 16 hours after 
LPS (10 μg/ml) stimulation. One-way ANOVA coupled to Bonferroni’s 
post tests (n = 6). (B–F) WT mice were i.v. injected with shEF2 or shΦ 
GFP+ lentiviral vectors. After 7 days, mice were injected with D-gal+LPS 
or saline. Data are means ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 
(2-way ANOVA coupled to Bonferroni’s post tests). (B) ELISA of TNF-α 
and IL-6 in mouse serum 6 hours after treatment (n = 6). (C) Represen-
tative livers and H&E-stained sections after removal at 6 hours after 
injection The chart presents hemorrhagic area as a percentage of the 
total area (n = 6). Scale bar: 50 μm. (D) Serum transaminase activity at 
6 hours after injection (n = 6). (E) Immunoblot analysis of liver extracts 
(n = 6). (F) Mouse survival after D-gal+LPS injection (n = 10). Survival 
curves were created with the Kaplan-Meier method and compared by 
log-rank (Mantel-Cox) test. (G) The MKK3/6-p38γ/δ-eEF2K pathway is 
necessary for LPS-induced hepatitis. LPS induces leukocyte egress 
from BM and cytokine/chemokine production in peripheral blood and 
by Kupffer cells. This leads to massive leukocyte infiltration in the liver 
and hepatocellular injury. TNF-α plays a dominant role in LPS-induced 
liver injury. Activation of the MKK3/6-p38γ/δ-eEF2K pathway in macro-
phages/Kupffer cells controls TNF-α production at the mRNA elonga-
tion level in acute inflammatory responses to LPS.
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perfusion of the liver (56). Primary monolayer cultures were established by 
plating 1.5 × 105 viable cells/cm2 in 6-well collagen IV–coated plates. After 
16 hours, primary hepatocytes were stimulated for 24 hours with TNF-α 
(20 ng/ml) plus CHX (100 μg/ml) or with 500 μl of macrophage-condi-
tioned medium for 12 hours. Neutrophil migration assays were performed 
using BD Falcon FluoroBlok 96 Multi-Well insert systems. Neutrophils 
were stained for 1 hour with 1.5 μM calcein AM. Then, 1 × 105 cells were 
plated per well in the upper chamber in 50 μl of culture medium without 
FBS. Lower chambers contained 200 μl of culture medium alone or supple-
mented with the chemoattractant (20 ng/ml TNF-α or 1/10 cytokine cock-
tail). Fluorescence emission was measured at different time points with 
a fluorescent plate reader with bottom-reading capability (Fluoroskan 
Ascent; Thermo Scientific).
Serum analysis. Serum activities of ALT and AST were measured using the 
ALT and AST Reagent Kit (Biosystems Reagents) with a Benchmark Plus 
Microplate Spectrophotometer. Serum concentrations of cytokines were 
measured by multiplexed ELISA with a Luminex 200 analyzer (Millipore).
Biochemical analysis. Tissue extracts were prepared using Triton lysis buf-
fer (20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 
2 mM EDTA, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 
1 mM phenylmethylsulfonyl fluoride, and 10 μg/ml aprotinin and leu-
peptin). Extracts (30 μg protein) and immunoprecipitates (prepared from 
2 mg protein) were examined by protein immunoblot analysis with anti-
bodies to ERK1/2, phospho-ERK1/2, phospho-MKK3/6, p38α MAPK, 
phospho-p38, phospho-hsp27, phospho-JNK1/2, JNK1/2, caspase 3, 
cleaved caspase 3, cleaved PARP, and phospho-eEF2 kinase (Ser366), all 
from Cell Signaling and MKK3 (BD Biosciences — Pharmingen), MKK6 
(Stressgen), and GAPDH and eEF2 (Santa Cruz Biotechnology Inc.). The 
anti-p38γ and p38δ antibodies were raised against the peptides PPRQL-
GARVPKETAL and PIARKDSRRRSGMKL, respectively, which correspond 
to the C termini of the proteins.
Immunohistochemistry. Livers were fixed in 4% paraformaldehyde, pro-
cessed, and embedded in paraffin. Sections (5 μm) were stained with H&E.
Isolation of liver-infiltrating mononuclear leukocytes. Mouse livers were col-
lected, and a single-cell suspension was obtained and passed through a 
70-μm strainer. Leukocytes were collected from the interphase of centri-
fuged Ficoll gradients. Cells were counted with a CASY Cell Counter (57). 
Then 106 Cells were labeled by surface staining (PE-conjugated anti-CD11b 
and PerCP-conjugated anti–Gr-1; Invitrogen), and another 106 cells were 
stimulated in vitro with LPS (10 μg/ml) plus brefeldin A,which inhibits 
protein transport from ER to Golgi, leading to the accumulation of protein 
inside the ER (BD GolgiPlug) (1:1000) for 2 hours. The LPS-stimulated 
cells were then labeled by surface staining (PE-conjugated anti-CD11b 
and PerCP-conjugated anti–Gr-1; Invitrogen), fixed, permeabilized, and 
stained for intracellular TNF-α (APC-conjugated anti–TNF-α from BD 
Biosciences) and IL-12 (PE-conjugated anti–IL-12 from BD Biosciences). 
Flow cytometry was performed with a FACScan cytofluorometer (FACS 
Canto BD), and data were examined using FlowJo software.
Phospho-p38 FACS analysis. Primary myeloid cells were isolated (neutrophils, 
BM macrophages, and Kupffer cells) and stimulated for 30 minutes with LPS 
(10 μg/ml). Cells were fixed overnight in 70% methanol at –20°C and stained 
with anti–phospho-p38 antibody (Cell Signaling) or control rabbit IgG fol-
lowed by FITC–anti-rabbit IgG. Signal was detected by flow cytometry.
RNA-immunoprecipitation assay. RAW 264.7 cells (mouse leukemic 
monocyte macrophage cell line) were stimulated with LPS (10 μg/ml) 
and RNA-immunoprecipitation assays (RIPs) were performed using anti-
bodies against eEF2 (Santa Cruz Biotechnology Inc.). The efficiency of 
immunoprecipitation was checked by immunoblot analysis. RNA was 
isolated from the input lysate, isotype control immunoprecipitate, and 
the anti-eEF2 immunoprecipitate. After reverse transcription, the levels of 
matory conditions. In starvation conditions, mTOR stops protein 
synthesis at the elongation step — the step that consumes most 
metabolic energy — by inhibiting eEF2, thereby preventing cell 
energy depletion. Less is known about the mechanisms involved in 
the termination of the inflammatory response once it has achieved 
its goal. This process needs to be rapidly regulated in order to 
avoid more tissue damage. Our results suggest that control of pro-
tein elongation might be an important mechanism by which cells 
rapidly shut down production of proinflammatory proteins that 
could extend tissue damage in the body, such as TNF-α during an 
inflammatory response. This might be an important mechanism 
by which cells tightly regulate cytokine production induced by 
stress kinases activated during inflammation.
In summary, we conclude that p38γ/δ in myeloid cells promote 
TNF-α production by activating its translation without changes 
in mRNA levels. This is achieved by phosphorylation of eEF2K, 
releasing the inhibitory action of this kinase on eEF2. This post-
transcriptional regulation might be an important mechanism 
regulating cytokine secretion during the innate immune response 
and provides potential targets for the treatment of liver diseases.
Methods
Mice. Mkk3–/– (B6.129-Map2k3tm1Flv) (47, 48) and Mkk6–/– (B6.129-Map2k6tm1Flv) 
mice (49) were as previously described (14). p38γ (B6.129-Mapk12tm1) and 
p38δ (B6.129-Mapk13tm1) mice were crossed with B6.129P2-Lyz2tm1(cre)Ifo/J 
and backcrossed for 10 generations to the C57BL/6J background (Jackson 
Laboratory) and genotyped by PCR analysis of genomic DNA. Radiation 
chimeras were generated by exposing recipient mice to 2 doses of ionizing 
radiation (525 Gy) and reconstituting them with 2 × 107 donor BM cells 
by injection into the tail vein. Hepatitis was induced by i.p. injection with 
50 μg/kg E. coli 0111:B LPS (Sigma-Aldrich) plus 1 g/kg D-gal (Sigma-Aldrich) 
or by i.v. injection with 10 μg/kg ΤΝF-α (R&D Systems) plus 1 g/kg GalN. 
When required, inhibitors were administered by i.p. injection at 15 mg/kg as 
previously reported (50, 51). For in vivo neutrophil depletion, 300 μg/mouse 
of anti-Gr1 or the same volume of saline were i.v. injected 24 hours before 
challenge with LPS. Specificity of the depletion of cell populations was deter-
mined by flow cytometry of blood samples collected during the experiment.
Lentivirus vector production and infection of mice. Lentiviruses were produced 
as described (52). Transient calcium phosphate cotransfection of HEK-
293 cells was done with the pGIZP empty vector or pGIZP.shEF2 vector 
( Thermo Scientific) together with pΔ8.9 and pVSV-G. The supernatants 
containing the LV particles were collected 48 and 72 hours after removal 
of the calcium phosphate precipitate and were centrifuged at 700 g at 4°C 
for 10 minutes and concentrated (×165) by ultracentrifugation for 2 hours 
at 121 986 g at 4°C (Ultraclear Tubes, SW28 rotor and Optima L-100 XP 
Ultracentrifuge; Beckman). Viruses were collected by adding cold sterile PBS 
and were titrated by qPCR.
Mice were injected in the tail vein with 200 μl lentiviral particles suspend-
ed in PBS. Seven days after infection, mice were injected with LPS+D-gal.
Cell culture. Primary BM-derived macrophages were prepared and cul-
tured as described previously (53). To isolate primary Kupffer cells from 
mouse livers, we performed collagenase perfusion and differential centrif-
ugation using Percoll (Pharmacia) as described previously (54). BM neu-
trophils were purified by positive selection using biotinylated GR-1 (BD 
Biosciences — Pharmingen) and MACS streptavidin microbeads (Miltenyi 
Biotec). Neutrophil purity was 95% or greater, as assessed by flow cytom-
etry (55). Cytokines in the culture medium were measured by multiplexed 
ELISA using a Luminex 200 analyzer (Millipore) and a mouse cytokine kit 
(Millipore). For primary hepatocyte isolation, liver parenchymal cells were 
prepared from 8- to 12-week-old anesthetized mice by in situ collagenase 
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TNF-α mRNA were determined by qRT-PCR. Relative mRNA levels were 
calculated by subtracting background from the level of the target mRNA 
and then using the standard ΔΔCT formula.
qRT-PCR. The expression of mRNA was examined by qRT-PCR using a 
7900 Fast Real Time thermocycler and FAST SYBR GREEN assays (Applied 
Biosystems). Relative mRNA expression was normalized to Gapdh mRNA 
measured in each sample. Hif-1α, Gr-1, KC (Cxcl1), Mip-2 (Cxcl2), Mcp-1, and 
Icam-1 were amplified using the primers shown in Supplemental Table 1.
Statistics. Differences between groups were examined for statistical sig-
nificance using 2-tailed Student’s t test or ANOVA coupled to Bonfer-
roni’s post-test. Kaplan-Meier analysis of survival was performed using 
the log-rank test.
Study approval. Animal studies were approved by the local ethics commit-
tee and by the IACUC of the University of Massachusetts Medical School. 
All animal procedures conformed to EU Directive 86/609/EEC and Rec-
ommendation 2007/526/EC regarding the protection of animals used for 
experimental and other scientific purposes, enacted under Spanish law 
1201/2005.
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